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Abstract
BACKGROUND: The aim of this paper is to present our experi-
ence concerning cooperation in the treatment of Slovak patients
with differentiated thyroid cancer in Slovak and Czech hospi-
tals. The objectives of this study were to demonstrate the means
of this cooperation and the results of therapy.
MATERIAL AND METHODS: From September 1991 to October
2005 in the Department of Nuclear Medicine in Ostrava 357 pa-
tients from the Slovak Republic with differentiated thyroid can-
cers (follicular and papillary) underwent complex therapy. They
were diagnosed and operated due to the cancer (near-total thy-
roidectomy and removal of lymph node metastases) in Slovak
hospitals. Then they were sent to the Department of Nuclear
Medicine in Ostrava in the Czech Republic. In this department
a radioiodine ablation of thyroid remnants, by means of the treat-
ment amount of radioiodine of a standard activity of 3.7 GBq,
was performed, and then a suppression and substitution thera-
py of thyroid hormones was started. After 36 months some
patients were examined by means of diagnostic whole body
scintigraphy after application of 300 MBq 131I. Some patients
were treated by means of a standard activity of 7.4 GBq 131I and
after 5 days whole body scintigraphy (WBS) was performed.
In both of these groups of patients the diagnostic or therapeutic
radioiodine application was done after withdrawal of thyroid hor-
mone treatment. If thyroglobulin levels were low and WBSs were
negative, patients were followed up in the Department of Nu-
clear Medicine in Martin. Patients with radioiodine accumulated
metastases were again treated with radioiodine in Ostrava.
If indicated, external radiation therapy targeted on the neck and
upper mediastinum was performed in the Slovak Republic,
in the University Hospital in Martin. Newly formed lymph node
metastases were surgically treated in Slovakia, too. Generally
we have very good treatment results. Also, economically our
partnership is cost effective. Our collaboration also successfully
continues after entrance of the Slovak Republic and the Czech
Republic to the European Union in 2004.
CONCLUSIONS: The results of this multi-centre study show that
international Czech and Slovak cooperation in the complex the-
rapy of patients with differentiated thyroid cancers is success-
ful, with high efficacy. The treatment results were very similar
to therapeutic results in our patients from the Czech Republic.
Key words: thyroid differentiated cancer, thyroidectomy,
radioiodine therapy, thyroid cancer, thyroid radioiodine
accumulation
Introduction
We present our experience concerning cooperation in the treat-
ment of Slovak patients with differentiated thyroid cancers (DTC)
in Slovak and Czech hospitals. Treatment capacities in Slovak
nuclear medicine departments are not sufficient for radioiodine
therapy and that is why these patients are sent for this therapy
to the Czech Republic nuclear medicine departments. The objec-
tives of this study are to demonstrate the means of this coopera-
tion and the results of the therapy. We concentrated on the co-
llaboration between the Department of Nuclear Medicine in Martin
in the Slovak Republic and the Department of Nuclear Medicine
in Ostrava in the Czech Republic.
Until 1991, patients with DTC were treated in Slovak hospitals
in two departments of nuclear medicine  in Bratislava and Mar-
tin. In 1991, in the department of nuclear medicine in Martin,
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a malfunction in the waste water liquidation system after radioio-
dine therapy occured. From this time patients with DTC could only
be followed up in Martin hospital and because of the small num-
ber of nuclear medicine beds in Slovak hospitals these patients
had to be treated by means of radioiodine application abroad
(in the Czech hospitals).
In our paper we present our knowledge on international coopera-
tion in the treatment of 357 patients from Slovakia who were treated
in the Department of Nuclear Medicine of the University Hospital
in Ostrava in the Czech Republic from September 1991 to October 2005.
Material and methods
Patients and procedure
From September 1991 to October 2005 357 patients from the
Slovak Republic with DTC underwent complex therapy. In Slovak
hospitals they were diagnosed and operated due to thyroid can-
cer (near-total thyroidectomy and removal of lymph node metastas-
es). Then they were sent to the Department of Nuclear Medicine
in Ostrava, Czech Republic.
In this department a radioiodine ablation of thyroid remnants
by means of the treatment standard activity of 3.7 GBq radioiodine
was performed and then a suppression and substitution therapy
of thyroid hormones was initiated. After 36 months 244 patients were
examined by means of diagnostic whole body scintigraphy after
application of 300 MBq 131I utilizing a dual-head SPECT gamma-
-camera E.CAM (Siemens, Erlangen, Germany) equipped with high
energy collimators; the scanning was performed 48 hours after ra-
dioiodine application (Fig. 1A, 2). In 243 patients diagnostic whole
body scintigraphy (WBS) was negative. One patient with accumu-
lated metastasis did not arrive, and the therapy was not done.
Figure 1. Woman aged 42 years with papillary thyroid cancer after thyroelimination. A. Diagnostic whole body scintigraphy; B. Post-therapeutic whole
body scintigraphy  markedly accumulated thyroid remnant.
A B
The rest of the patients (113 patients) with accumulated metastases
or radioiodine accumulated thyroid remnant were treated by means
of standard activity of 7.4 GBq 131I (25 months after radioiodine
thyroid ablation) and post-therapeutic WBS was performed after
5 days (Fig. 1B, 35). In both these groups of patients the diagnostic
or therapeutic radioiodine application was done after withdrawal
from thyroid hormone treatment. Thyroid stimulating hormone (TSH),
free thyroxin (FT4), total triiodothyronin (TT3), thyroglobulin (Tg) and
antithyroglobulin antibodies (TgAb) were tested in plasma from
all patients. From September 1991 to October 2005 we treated
357 Slovak patients (70 men and 287 women, average age 48.4 years)
in Ostrava with radioiodine, in addition to Czech patients. 66 pa-
tients had follicular cancers and 291 papillary cancers (included
77 patients with follicular variants of papillary cancer).
Results
From a total of 357 patients 231 had one thyroidectomy,
106 pts had two surgeries and 20 patients had three thyroidecto-
mies (Table 1).
Eighty-seven patients (24.4%) had radioiodine accumulating
metastases: 78 patients (21.8%) in lymph nodes, 2 patients (0.56%)
in lymph nodes and bones, 3 patients (0.84%) in lymph nodes,
lung and bone, one patient (0.28%) in lymph node and liver, one
patient (0.28%) in lymph node, lung and liver and two pts (0.56%)
in bones (Table 2).
After thyro-elimination, diagnostic whole body scintigraphy
without radioiodine therapy was done in 244 patients  WBS
in 243 patients was negative; in one patient accumulated lymph
node metastasis was found. Following therapy was not performed,
as the patient did not arrive.
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Radioiodine therapy
Single 131I therapy was done in 68 patients  post-therapeu-
tic or diagnostic whole body scintigrams were negative in 67 pa-
tients, one patient had pulmonary metastasis. After two radioiod-
ine therapies in 6 patients from 22 patients there were lymph node
or pulmonary metastases or a combination of lymph node, pul-
monary and liver metastases. The other 16 patients had negative
Figure 2. A 43 year-old man with papillary thyroid cancer. Diagnostic
scintigraphy after 300 MBq of 131I. Without thyroid remnant or accumulated
metastases.
Table 1. Number of one, two or three thyroidectomies
THYROIDECTOMY
One surgery 231
Two surgeries 106
Three surgeries 20
Total 357
Figure 4. Woman aged 55 years with papillary thyroid cancer. Scintigraphy
after therapy 7.4 GBq 131I. Thyroid remnant and accumulated pulmonary
metastases.
Figure 5. Woman aged 64 years with follicular thyroid cancer. Scintigraphy
after therapy 7.4 GBq 131I. Accumulated pulmonary and bone metastases.
Figure 3. Woman aged 65 years. Repeated radioiodine therapy for pulmonary
metastasis of follicular thyroid cancer. Scintigraphy after therapy 7.4 GBq 131I.
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post-therapeutic WBS. After three therapies two patients had
metastases in bones or lung. After four therapies in one patient
(only one received four therapies) we found thyroid remnants.
After 5 therapies in 4 patients from the eight, lymph nodal or pulmo-
nary metastases were shown, and the other 4 patients were with-
out accumulated metastases. One patient was treated six times.
After the sixth radioiodine therapy this patient showed pulmonary
metastasis. One patient was treated 7 times for liver metastasis.
All 4 patients, after eight and nine therapies, had negative whole
body scans. One patient, after 12 therapies, showed lymph node
metastasis (Table 3).
All patients with metastases shown after these therapies will
be treated by radioiodine again in Ostrava, Czech Republic.
Discussion
Thyroid carcinoma accounts for approximately 1% of all hu-
man cancers. The most often there are DTCs, which are divided
according to histopathological classification into follicular and
papillary carcinomas.
DTC often forms metastases in lymph nodes on the neck, dis-
tant metastases in lungs and bones. Other distant metastases
 to the brain, kidneys, skin and liver [1] are rare.
Radioiodine therapy is used in patients with DTC for ablation
of thyroid remnants and for treatment of persistent or recurrent
disease. Its use depends upon the ability of neoplastic cells
to concentrate radioiodine.
Favourable responses to treatment are characterised by par-
allel decreases in tumour volume, 131I uptake and serum Tg levels.
In contrast, a decrease in 131I uptake without a parallel decrease,
or with an increase in tumour volume, indicates tumour progres-
sion. The overall survival rate at 10 years from the time of detec-
tion of metastases ranges from 2540%. Distant metastases
appear to be the main cause of thyroid cancer-specific mortality, but
are compatible with long-term survival in numerous patients [24].
Prognostic variables for survival are strongly interrelated, and
multivariate analyses have shown that four variables have
a favourable impact: young age at the time of metastases detec-
tion, the papillary or follicular histological type of the primary tu-
mour, the presence of 131I uptake, and small extent of the disease.
The survival rate at 10 years was 93% in patients who achieved
a complete response but only 14% in those who did not [2]. This
finding does not signify that prolonged survival can be imputed
to therapy alone, since response to treatment was also related
to other favourable prognostic factors. All patients who survived
15 years or more after the discovery of the metastases, however,
had been treated with 131I. Without radioiodine therapy, it is very
unlikely that such a large number of patients would be alive
for such a long period of time after the discovery of metastases [2].
For follow-up of patients with DTC, after the elimination of the
thyroid gland, the regular determination of serum levels of thyro-
globulin is important; this is a sensitive and specific tumour mar-
ker. In a small number of cases it can be false negative. The thy-
roglobulin assessment is periodically supplemented by whole body
scintigraphy after a diagnostic amount of radioiodine, after with-
drawal of thyroid hormone treatment. The possibly present func-
tional metastases are stimulated by subsequent increased level
of TSH. Whole body scintigraphy is false negative in non-func-
tional metastases. In this situation the determination of serum thy-
roglobulin helps [5].
In diagnosis, therapy and long-term follow up of patients we
use procedures which are ordinarily recommended and used
in the therapy of DTC throughout the world [611].
In preparation of patients for radioiodine therapy we did not
use Thyrogen, recombinant human TSH (rhTSH) [12], especially
for economic reasons (Thyrogen is not reimbursed by our health
insurance system).
Table 2. Number of various types of accumulated metastases
RADIOIODINE ACCUMULATED METASTASES
In lymph nodes 78
In lymph nodes and bones 2
In lymph nodes, lung and bone 3
In lymph node and liver 1
In lymph node, lung and liver 1
In bones 2
Total 87
Table 3. Number of 131I treatments and whole body scans in our patients with metastases or radioiodine-accumulating thyroid remnants
131I therapy 7.4 GBq Number of patients Post-therapeutic or diagnostic WBS
Negative Positive Localization of metastasis
1st 68 67 1 Lung
2nd 22 16 6 Lymph node, lung, liver
3rd 2 2 Bone, lung
4th 1 1 Thyroid remnant
5th 8 4 4 Lymph node, lung
6th 1 1 Lung
7th 1 1 Liver
8th 4 4
9th 4 4
12th 1 1 Lymph node
Total 113 96 (85%) 17 (15%)
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Conclusions
In conclusion we generally had very good treatment results
in patients from Slovakia which did not differ from the results
achieved in patients from the Czech Republic.
Dur to this, some facts should be remembered. We took these
facts into consideration during the treatment of Slovak patients which
for us are, today, patients from abroad. Until the end of 1992 Czech
and Slovak people lived in one state  Czechoslovakia, which sub-
sequently was divided into two states  the Czech and the Slovak
Republics. During the delivery of information which was necessary
for successful therapy generally there were no problems in com-
munication with patients due to the similarity of the Slovak and Czech
languages. After thirteen years of division of the Czechoslovak
Republic principles of health care maintenance did not substantial-
ly differ. Also, their similar lifestyles and living standards did not
significantly change. Some differences in the reform of health care
and health insurance induced predominantly administrative draw-
backs in therapeutic supply. In about 10% of patients the thyroab-
lative radioiodine amount was not given in the optimal interval
of 6 weeks after thyroidectomy but after a further two to four weeks.
Our partnership is also effective economically. Our collabora-
tion has successfully continued after the entrance of the Slovak
Republic and the Czech Republic to the European Union in 2004.
The results of this multi-centre study show that international Czech
and Slovak cooperation in the complex therapy of patients with
differentiated thyroid cancers is successful, with high efficacy.
The treatment results were very similar to therapeutic results in our
patients from the Czech Republic.
The interest of our presentation lies on the following:
 by the WBS we found no metastases in the kidneys, brain
or the skin [1];
 in accordance with our experience, a favourable response
to treatment was characterised by a parallel decrease of the
tumour volume, 131I uptake and serum Tg levels [13];
 while preparing patients for radioiodine therapy we did not
use recombinant human TSH for administrative and financial
reasons [12];
 after one to twelve radioiodine therapies the WBS in 85 per-
cent of patients was negative with normalization of Tg levels
indicating successful 131I therapy [14];
 patients may take up to 66.688.8 GBq of 131I within a 10 year
period [15].
This is a randomised study. Selected patients will be studied
and presented on forthcoming occasions.
This paper was presented as an oral presentation in WFNMB/
/WRPTC International Conference on Radiopharmaceutical Thera-
py (ICRT-2005), Limassol, Cyprus 1114 October 2005 [16].
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